2nd Cervical Cancer Vaccine on the Way?
Study Shows Cervarix Protects Against Virus That Can Cause Cervical Cancer
WebMD News Archive
The newly reported findings were published in the latest online issue of the
They represent an interim analysis from Glaxo's ongoing international trial
evaluating the effectiveness of Cervarix.
A total of 18,644 women from 14 countries were included in the trial. All of
the women were between the ages of 15 and 25 at study entry.
Young girls who are not yet sexually active or who have just become sexually
active are considered the target group for vaccination.
The FDA approved Gardasil for girls and women aged 9 to 26, but Merck is
testing the vaccine in boys because men get genital warts and pass HPV
infection to their partners.
In the Cervarix trial, about half the women received the three-dose
immunizations with the HPV vaccine and half were not vaccinated against
After an average follow-up of 15 months, the vaccine was found to be 90.4%
effective against precancerous cervical lesions caused by HPV-16 and
When researchers further analyzed the lesions they identified, none
occurring in the cervical cancer vaccine recipients were found to be caused by
the two HPV types, indicating 100% effectiveness, Tursi says.
Jorma Paavonen, MD, who is leading the ongoing international trial, tells
WebMD that the interim results are better than he would have expected.
The women in the study will be followed for four years. Women participating
in other studies of the vaccine have been followed for just over five years,
with little evidence of waning protection, he says.
"It is too early to say if boosters will be needed at 10 years or 15
years, but it looks like protection is lasting" he says.
Cervical Cancer Protection for All
An editorial accompanying the study points out that the public health impact
of HPV vaccination is still unclear.
"Certainly vaccinated women will still require cervical screening [Pap
tests] and appropriate follow-up," write Jessica Kahn, MD, and Robert Burk,
MD. Kahn and Burk also questioned whether the women who need a cervical cancer
vaccine most will get it.
"Poverty is strongly associated with high-risk HPV infection and
cervical cancer," they write. "If those who live in poverty cannot
access a highly effective intervention such as HPV vaccines, disparities could
Tursi tells WebMD that Glaxo has been committed to making its vaccines
available to those who can least afford them.
"Glaxo delivers 80% of vaccines to the developing world. We have a
strong commitment to the developing world," he says. "And within the
U.S. in those areas that will require increased attention, we are poised to